Sarkari Naukri

28 August 2021 Current Affairs:International Vaccine Institute has announced that Bharat Biotech’s Chikungunya vaccine candidate (BBV87) has entered into Phase II & III clinical trials. Currently, there is no industrial chikungunya vaccine.

Highlights:
♦ BBV87 is an inactivated virus vaccine, that is similar to Covaxin.
♦ Inactivated vaccines incorporate viruses whose genetic fabric has been destroyed with the aid of heat, chemicals or radiation so they cannot infect cells and replicate, however can nevertheless trigger an immune response.
♦ Bharat Biotech’s Chikungunya vaccine candidate was once developed in partnership with the International Vaccine Institute (IVI).
♦ Development of Chikungunya Vaccine is an initiative of the United Nations Development Programme (UNDP), as part of the Global Chikungunya Vaccine Clinical Development Program (GCCDP).
♦ It was funded with the aid of the Coalition for Epidemic Preparedness Innovations (CEPI) with aid from the Ind-CEPI mission of the Biotechnology Department, Government of India.